Rotigotine

Neupro, Leganto (rotigotine) is a small molecule pharmaceutical. Rotigotine was first approved as Neupro on 2006-02-15. It is used to treat parkinson disease and restless legs syndrome in the USA. It has been approved in Europe to treat parkinson disease and restless legs syndrome. The pharmaceutical is active against D(2) dopamine receptor. In addition, it is known to target D(1B) dopamine receptor, D(4) dopamine receptor, D(3) dopamine receptor, and D(1A) dopamine receptor. Neupro's patents are valid until 2032-03-01 (FDA).